Future Science OA · 2015 · 31 citations · 22 references
Life SciencesCell BiologyNeuroscienceDrug DeliveryEndocytosisIntracellular TransportBlood-brain Barrier BiologyBlood-brain Barrier DeliveryCellular UptakeLiposome-based DeliveryProtein TargetingReceptor-mediated EndocytosisBlood-brain Barrier PermeabilityBlood-brain Barrier Uptake MechanismsCarrier-mediated Transport Across The Blood-brain BarrierCarrier-mediated Transport At The Blood-brain BarrierLipid Nanoparticle DeliveryLipid Nanoparticle UptakeNanoparticle Cellular UptakeTargeted Delivery Across The Blood-brain Barrier
AIM: The present study was designed to test the cellular uptake of PEGylated liposomes targeted to transferrin receptor and to α-synuclein by a cell model of the blood-brain barrier (BBB). MATERIALS & METHODS: PEGylated immunoliposomes were prepared with anti-transferrin receptor OX26 and anti-α-synuclein LB509 antibodies to overcome the BBB in Parkinson's disease. RESULTS: The doubly targeted immunoliposomes bind to transferrin receptor and to α-synuclein protein, as assessed by ELISA assays. We establish that 40% of an encapsulated tested drug (epigallocatechin-3-gallate) is released in a time frame of 44 h, which is reasonable for sustained release. The cellular uptake of doubly targeted immunoliposomes in cultured brain endothelial cells hCMEC/D3 was two-times more efficient than that of PEGylated liposomes. CONCLUSION: Immunoliposomes targeted to BBB receptors and to α-synuclein could potentially enable the transport of drugs across the BBB and reach one of the drug targets in Parkinson's disease.
22
Daniela Elisabeth Eigenmann, Gongda Xue, Kwang S. Kim et al. · Fluids and Barriers of the CNS · 2013 · 429 citations · Full text
Medicine, Neuroscience, Pharmacology +17